NCT06968338View on ClinicalTrials.gov

A Study to Assess the Safety of ARGX-213 in Healthy Volunteers

PHASE1RecruitingINTERVENTIONAL

Enrollment

72

Participants

Timeline

Start Date

April 11, 2025

Primary Completion Date

January 6, 2026

Study Completion Date

January 6, 2026

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL

ARGX-213

Intravenous or subcutaneous administrations of ARGX-213

OTHER

Placebo

Intravenous or subcutaneous administrations of placebo

Trial Locations (1)

QC H3P 3P1

RECRUITING

Altasciences, Montreal

Sponsors

Lead Sponsor

All Listed Sponsors

lead

argenx

INDUSTRY

NCT06968338 - A Study to Assess the Safety of ARGX-213 in Healthy Volunteers | Biotech Hunter | Biotech Hunter